WO2026002087 - MYT1 KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2026/002087
Publication Date
02.01.2026
International Application No.
PCT/CN2025/103691
International Filing Date
26.06.2025
Title **
[English]
MYT1 KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF
[French]
INHIBITEUR DE MYT1 KINASE, COMPOSITION PHARMACEUTIQUE ASSOCIÉE ET UTILISATION ASSOCIÉE
[Chinese]
Myt1激酶抑制剂、其药物组合物及其用途
Applicants **
SUNSHINE LAKE PHARMA CO., LTD.
Inventors
ZHANG, Weihong
PENG, Hongtao
WU, Yang
XIE, Hongpeng
PENG, Dahua
YE, Weiliang
DENG, Weikang
ZENG, Huiting
Priority Data
202410843700.0
27.06.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2274 | |
| EPO | Filing, Examination, Granting | 16084 | |
| Japan | Filing, Examination, Granting | 2338 | |
| South Korea | Filing, Examination, Granting | 2536 | |
| USA | Filing, Examination, Granting | 4940 |
Total:
28,172
Contact Us
Abstract[English]
The present invention belongs to the pharmaceutical field. Specifically, provided are an Myt1 kinase inhibitor compound, a pharmaceutical composition thereof, and the use thereof. Specifically, provided is a compound of formula (I) or a stereoisomer, tautomer, nitrogen oxide, solvate, metabolite, pharmaceutically acceptable salt or prodrug thereof, wherein each variable has the meaning described in the description. The compound and the pharmaceutical composition thereof, as an Myt1 kinase inhibitor, can be used in the preparation of a drug for preventing or treating Myt1-associated diseases, and can particularly be used in the preparation of a drug for preventing or treating cancers.[French]
La présente invention appartient au domaine pharmaceutique. Plus particulièrement, l'invention concerne un composé inhibiteur de Myt1 kinase, une composition pharmaceutique de celui-ci, et son utilisation. Plus particulièrement, l'invention concerne un composé de formule (I) ou un stéréoisomère, un tautomère, un oxyde d'azote, un solvate, un métabolite, un sel pharmaceutiquement acceptable ou un promédicament de celui-ci, chaque variable ayant la signification décrite dans la description. Le composé et la composition pharmaceutique de celui-ci, en tant qu'inhibiteur de la kinase Myt1, peuvent être utilisés dans la préparation d'un médicament destiné à la prévention ou au traitement de maladies associées à Myt1, et peuvent en particulier être utilisés dans la préparation d'un médicament destiné à la prévention ou au traitement de cancers.[Chinese]
属于药物领域，具体地，提供了一种Myt1激酶抑制剂化合物、其药物组合物及其用途。具体地，提供了一种式(I)化合物或其立体异构体、互变异构体、氮氧化物、溶剂化物、代谢产物、药学上可接受的盐或前药，其中各变量具有说明书所述的含义。所述的化合物和其药物组合物作为Myt1激酶抑制剂可用于制备用于预防或治疗Myt1相关疾病的药物，尤其可用于制备用于预防或治疗癌症的药物。